Literature DB >> 12030369

Intracardiac expression of neutral endopeptidase.

V Raizada1, W Luo, B J Skipper, P G McGuire.   

Abstract

Neutral endopeptidase (NEP), a proteolytic enzyme, is known to degrade several peptides which control cardiovascular homeostasis. This is a preliminary study of the pattern of the intracardiac regional expression of the NEP gene in the normal heart, and the age-related changes in this expression in the cardiac regions. The relative abundance of NEP mRNA was determined by RT-PCR in the right atrium (RA), right ventricle (RV), left atrium (LA), left ventricle (LV) and interventricular septum (IVS) in 2-month-old (young) and 12-month-old (advanced-age adult) Wistar Kyoto (WKY) rats. The NEP gene was expressed in all 5 cardiac regions in both age groups. In young rats, the NEP expression level was lowest in the RA; this level was significantly lower than in the septum (p < 0.05). In the advanced-age adult rats, the level was lowest in the LA; this level also was significantly lower than in the septum (p < 0.05). The level in the RA in advanced-age rats was higher than that in the young rats (p < 0.01), but the levels in other regions were not significantly different between the young rats and advanced-age adult rats. Our study showed that the NEP gene was expressed in all cardiac regions of both young rats and advanced-age adult rats. However, the regional distribution of the gene was different in each age group. The region-specific expression of the NEP gene and the age-related regional changes in the expression may be due to the structural and functional characteristics of the various regions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12030369     DOI: 10.1023/a:1014815204763

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  9 in total

1.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

2.  Kallidin- and bradykinin-degrading pathways in human heart: degradation of kallidin by aminopeptidase M-like activity and bradykinin by neutral endopeptidase.

Authors:  J O Kokkonen; A Kuoppala; J Saarinen; K A Lindstedt; P T Kovanen
Journal:  Circulation       Date:  1999-04-20       Impact factor: 29.690

3.  Establishment of a common acute lymphoblastic leukemia cell line (LC4-1) and effects of phorbol myristate acetate (PMA) on the surface antigen expression of the cell line.

Authors:  T Yoshimura; M Mayumi; T Yorifuji; K M Kim; T Heike; T Miyanomae; K Shinomiya; H Mikawa
Journal:  Am J Hematol       Date:  1987-09       Impact factor: 10.047

4.  Down regulation of kidney neutral endopeptidase mRNA, protein and activity during acute renal failure: possible mechanism for ischemia-induced acute renal failure in rats?

Authors:  P Nambi; M Pullen; H L Wu; U Prabhakar; L Hersh; M Gellai
Journal:  Mol Cell Biochem       Date:  1999-07       Impact factor: 3.396

5.  Phorbol diesters regulate expression of the membrane neutral metalloendopeptidase (EC 3.4.24.11) in rabbit synovial fibroblasts and mammary epithelial cells.

Authors:  Z Werb; E J Clark
Journal:  J Biol Chem       Date:  1989-06-05       Impact factor: 5.157

6.  Do hypertension and aging have a similar effect on the myocardium?

Authors:  E G Lakatta
Journal:  Circulation       Date:  1987-01       Impact factor: 29.690

7.  Down-regulation and inactivation of neutral endopeptidase 24.11 (enkephalinase) in human neutrophils.

Authors:  E G Erdös; B Wagner; C B Harbury; R G Painter; R A Skidgel; X G Fa
Journal:  J Biol Chem       Date:  1989-08-25       Impact factor: 5.157

8.  Neutral endopeptidase in the heart. Neutral endopeptidase inhibition prevents isoproterenol-induced myocardial hypoperfusion in rats by reducing bradykinin degradation.

Authors:  G Piedimonte; J A Nadel; C S Long; J I Hoffman
Journal:  Circ Res       Date:  1994-10       Impact factor: 17.367

Review 9.  Neutral endopeptidase inhibitors and atrial natriuretic peptide.

Authors:  G Achilihu; W H Frishman; A Landau
Journal:  J Clin Pharmacol       Date:  1991-08       Impact factor: 3.126

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.